Identifying a system of predominant negative symptoms: Network analysis of three randomized clinical trials

Schizophrenia Research

Volumn 178, Issue 1-3, 2016, Pages 17-22

  Levine, Stephen Z ^a   Leucht, Stefan ^b  

^a UNIVERSITY OF HAIFA   (Israel)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Clinical trial; Network analysis; Predominant negative symptoms; Psychometrics; Scale for the assessment of negative symptoms; Symptom severity

Indexed keywords

AMISULPRIDE; NEUROLEPTIC AGENT; PLACEBO;

ADULT; APATHY; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FUNCTIONAL CONNECTIVITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOMS SCORE; SCHIZOPHRENIA; SCORING SYSTEM; SYMPTOMATOLOGY; META ANALYSIS; NETWORK META-ANALYSIS; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

HUMANS; NETWORK META-ANALYSIS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84995468921     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2016.09.002     Document Type: Article

References (46)

1. Alphs, L., An industry perspective on the nimh consensus statement on negative symptoms. Schizophr. Bull. 32:2 (2006), 225–230.
2. Andreasen, N.C., Scale for the Assessment of Negative Symptoms. 1983, University of Iowa, Iowa City.
3. Borsboom, D., Cramer, A.O., Schmittmann, V.D., Epskamp, S., Waldorp, L.J., The small world of psychopathology. PLoS One, 6(11), 2011, e27407.
4. Bowie, C.R., Reichenberg, A., Patterson, T.L., Heaton, R.K., Harvey, P.D., Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am. J. Psychiatry 163:3 (2006), 418–425.
5. Boyer, P., Lecrubier, Y., Puech, A.J., Dewailly, J., Aubin, F., Treatment of negative symptoms in schizophrenia with amisulpride. Br. J. Psychiatry 166:1 (1995), 68–72.
6. Clamor, A., Schlier, B., Kother, U., Hartmann, M.M., Moritz, S., Lincoln, T.M., Bridging psychophysiological and phenomenological characteristics of psychosis - preliminary evidence for the relevance of emotion regulation. Schizophr. Res. 169:1–3 (2015), 346–350.
7. Core R Team, R: A Language and Environment for Statistical Computing. 2012, 2014, R Foundation for Statistical Computing, Vienna, Austria 3-900051-07-0.
8. Costantini, G., Epskamp, S., Borsboom, D., Perugini, M., Mottus, R., Waldorp, L.J., Cramer, A.O.J., State of the art personality research: a tutorial on network analysis of personality data in r. J. Res. Pers. 54 (2015), 13–29.
9. Danion, J.M., Rein, W., Fleurot, O., Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride study group. Am. J. Psychiatry 156:4 (1999), 610–616.
10. Epskamp, S., Cramer, A.O., Waldorp, L.J., Schmittmann, V.D., Borsboom, D., Qgraph: network visualizations of relationships in psychometric data. J. Stat. Softw. 48:4 (2012), 1–18.
11. Ferrier, I.N., Roberts, G.W., Crow, T.J., Johnstone, E.C., Owens, D.G., Lee, Y.C., O'Shaughnessy, D., Adrian, T.E., Polak, J.M., Bloom, S.R., Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia. Life Sci. 33:5 (1983), 475–482.
12. Fried, E.I., Epskamp, S., Nesse, R.M., Tuerlinckx, F., Borsboom, D., What are ‘good’ depression symptoms? Comparing the centrality of dsm and non-dsm symptoms of depression in a network analysis. J. Affect. Disord. 189 (2015), 314–320.
13. Furukawa, T.A., Levine, S.Z., Tanaka, S., Goldberg, Y., Samara, M., Davis, J.M., Cipriani, A., Leucht, S., Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry 72:1 (2015), 14–21.
14. Fusar-Poli, P., Papanastasiou, E., Stahl, D., Rocchetti, M., Carpenter, W., Shergill, S., McGuire, P., Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr. Bull. 41:4 (2015), 892–899.
15. Harvey, P.D., Koren, D., Reichenberg, A., Bowie, C.R., Negative symptoms and cognitive deficits: what is the nature of their relationship?. Schizophr. Bull. 32:2 (2006), 250–258.
16. Jones, S.R., Fernyhough, C., Neural correlates of inner speech and auditory verbal hallucinations: a critical review and theoretical integration. Clin. Psychol. Rev. 27:2 (2007), 140–154.
17. Keefe, R.S., Harvey, P.D., Lenzenweger, M.F., Davidson, M., Apter, S.H., Schmeidler, J., Mohs, R.C., Davis, K.L., Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: negative symptoms. Psychiatry Res. 44:2 (1992), 153–165.
18. Kelley, M.E., van Kammen, D.P., Allen, D.N., Empirical validation of primary negative symptoms: independence from effects of medication and psychosis. Am. J. Psychiatry 156:3 (1999), 406–411.
19. Kennedy-Martin, T., Curtis, S., Faries, D., Robinson, S., Johnston, J., A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials, 16, 2015, 495.
20. Kirkpatrick, B., Fischer, B., Subdomains within the negative symptoms of schizophrenia: commentary. Schizophr. Bull. 32:2 (2006), 246–249.
21. Kirkpatrick, B., Fenton, W.S., Carpenter, W.T. Jr., Marder, S.R., The nimh-matrics consensus statement on negative symptoms. Schizophr. Bull. 32:2 (2006), 214–219.
22. Kossakowski, J.J., Epskamp, S., Kieffer, J.M., van Borkulo, C.D., Rhemtulla, M., Borsboom, D., The application of a network approach to health-related quality of life (hrqol): introducing a new method for assessing hrqol in healthy adults and cancer patients. Qual. Life Res., 2015.
23. Kraepelin, E., Dementia Praecox and Paraphrenia. 1971, Krieger, New York.
24. Kring, A.M., Gur, R.E., Blanchard, J.J., Horan, W.P., Reise, S.P., The clinical assessment interview for negative symptoms (cains): final development and validation. Am. J. Psychiatry 170:2 (2013), 165–172.
25. Leucht, S., Corves, C., Arbter, D., Engel, R.R., Li, C., Davis, J.M., Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:9657 (2009), 31–41.
26. Levine, S.Z., Leucht, S., Delayed- and early-onset hypotheses of antipsychotic drug action in the negative symptoms of schizophrenia. Eur. Neuropsychopharmacol. 22:11 (2012), 812–817.
27. Levine, S.Z., Leucht, S., Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms. Schizophr. Res. 145:1–3 (2013), 125–127.
28. Levine, S.Z., Leucht, S., Psychometric analysis in support of shortening the scale for the assessment of negative symptoms. Eur. Neuropsychopharmacol. 23:9 (2013), 1051–1056.
29. Levine, S.Z., Leucht, S., Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials. Schizophr. Res. 156:1 (2014), 107–114.
30. Loo, H., Poirier-Littre, M.F., Theron, M., Rein, W., Fleurot, O., Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br. J. Psychiatry 170 (1997), 18–22.
31. Marder, S.R., Davis, J.M., Chouinard, G., The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the north american trials. J. Clin. Psychiatry 58:12 (1997), 538–546.
32. Marder, S.R., Daniel, D.G., Alphs, L., Awad, A.G., Keefe, R.S., Methodological issues in negative symptom trials. Schizophr. Bull. 37:2 (2011), 250–254.
33. Marques, T.R., Levine, S.Z., Reichenberg, A., Kahn, R., Derks, E.M., Fleischhacker, W.W., Rabinowitz, J., Kapur, S., How antipsychotics impact the different dimensions of schizophrenia: a test of competing hypotheses. Eur. Neuropsychopharmacol. 24:8 (2014), 1279–1288.
34. McGuire, P.K., Silbersweig, D.A., Wright, I., Murray, R.M., Frackowiak, R.S., Frith, C.D., The neural correlates of inner speech and auditory verbal imagery in schizophrenia: relationship to auditory verbal hallucinations. Br. J. Psychiatry 169:2 (1996), 148–159.
35. Mueser, K.T., Sayers, S.L., Schooler, N.R., Mance, R.M., Haas, G.L., A multisite investigation of the reliability of the scale for the assessment of negative symptoms. Am. J. Psychiatry 151:10 (1994), 1453–1462.
36. Newman, M.E., Girvan, M., Finding and evaluating community structure in networks. Phys. Rev. E Stat. Nonlinear Soft Matter Phys., 69(2 Pt 2), 2004, 026113.
37. Peralta, V., Cuesta, M.J., de Leon, J., Positive and negative symptoms/syndromes in schizophrenia: reliability and validity of different diagnostic systems. Psychol. Med. 25:1 (1995), 43–50.
38. Pogue-Geile, M.F., Harrow, M., Negative symptoms in schizophrenia: their longitudinal course and prognostic importance. Schizophr. Bull. 11:3 (1985), 427–439.
39. Rabany, L., Weiser, M., Werbeloff, N., Levkovitz, Y., Assessment of negative symptoms and depression in schizophrenia: revision of the SANS and how it relates to the panss and cdss. Schizophr. Res. 126:1–3 (2011), 226–230.
40. Rabinowitz, J., Schooler, N., Algorithms/Flags for Rating Scales Used in CNS Clinical Trials. 2016, International Society for CNS Clinical Trials and Methodology, Washington DC.
41. Rabinowitz, J., Levine, S.Z., Garibaldi, G., Bugarski-Kirola, D., Berardo, C.G., Kapur, S., Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of catie data. Schizophr. Res. 137:1–3 (2012), 147–150.
42. Rabinowitz, J., Schooler, N., ISCTM working group, Increasing Signal Detection in Clinical Trials: Improving Fidelity of Instruments, International Society for CNS Clinical Trials and. 2016, Methodology, Washington DC.
43. Sayers, S.L., Curran, P.J., Mueser, K.T., Factor structure and construct validity of the scale for the assessment of negative symptoms. Psychol. Assess. 8:3 (1996), 269–280.
44. Toomey, R., Kremen, W.S., Simpson, J.C., Samson, J.A., Seidman, L.J., Lyons, M.J., Faraone, S.V., Tsuang, M.T., Revisiting the factor structure for positive and negative symptoms: evidence from a large heterogeneous group of psychiatric patients. Am. J. Psychiatry 154:3 (1997), 371–377.
45. van Borkulo, C., Boschloo, L., Borsboom, D., Penninx, B.W., Waldorp, L.J., Schoevers, R.A., Association of symptom network structure with the course of longitudinal depression. JAMA Psychiatry, 2015, 1219–1226.
46. van Borkulo, C., Boschloo, L., Borsboom, D., Penninx, B.W., Waldorp, L.J., Schoevers, R.A., Association of symptom network structure with the course of longitudinal depression. JAMA Psychiatry 72:12 (2015), 1219–1226.